ABL Diagnostics Announces Block Transactions and Strategic Goals
On Monday 4 March, 2024 at 8am, ABL Diagnostics (FR001400AHX6) (“ABLD” or the “Company”) announced that three block transactions have been reported to ONDE, the central information filing system of the Autorité des Marchés Financiers (AMF), since August 2023. The transactions, totaling 59,651 shares of common stock, are publicly available on the AMF’s decisions and notifications database website (https://bdif.amf-france.org/en).
These block trades were conducted by ABLD’s parent company, Advanced Biological Laboratory (ABL), a privately held company headquartered in Luxembourg. ABL is the largest shareholder of ABLD, holding over 99% of the shares.
Mr. Ronan Boulmé, GRC Director of the ABL Group, stated, “These transactions – 0.37% of the total common shares – are in line with our commitment to the AMF to sell up to thirty percent (30%) of our common shares to create a free float of ABLD shares. This goal continues to be pursued through ongoing efforts and partnerships.” He added, “The recent block trades mark the beginning of a strategic journey for ABL Diagnostics as it embarks on its next phase of growth and development. These investments will fuel ABL Diagnostics’ continued efforts to pioneer and deliver state-of-the-art diagnostic solutions in collaboration with strategic partners worldwide.”
ABL Diagnostics is a worldwide leading international company that offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection and genotyping. Their products, including UltraGene® for Polymerase Chain Reaction (PCR) and DeepChek® for DNA sequencing, are used for a variety of applications, such as HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, and microbiome analyses. ABL Diagnostics also offers clinical specimen collection kits and digital solutions, such as Nadis®, an Electronic Medical Record (EMR) system.
The company’s entire line of products is marketed worldwide through their own sales team and a network of exclusive distributors. ABL Diagnostics serves clients in academic clinical pathology labs, private reference labs, and researchers who seek innovative and robust microbiology solutions.
Based in Woippy, ABL Diagnostics is a public company listed on compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). For more information, please visit www.abldiagnostics.com.
CONTACTS
ABL Diagnostics
info@abldiagnostics.com
Dr Chalom Sayada, CEO and Founder of ABL SA, Board Director ABLD
Tel: + 33 (0)7 83 64 68 50
FORWARD-LOOKING STATEMENT
This press release contains forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers to be reasonable, but there can be no assurance that they will be verified. The statements are subject to numerous risks, including those listed in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on the ABL Diagnostics website (www.abldiagnostics.com) and the development of economic conditions, financial markets, and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from the forward-looking statements.
This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe, or a solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a violation of applicable laws. Individuals in possession of this press release must inquire about any local restrictions and comply with them.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.